
Opinion|Videos|August 6, 2024
Therapies Beyond BCG: FDA-Approved and Emerging Options
Experts discuss available therapies beyond BCG.
Advertisement
Episodes in this series

Video content above is prompted by the following question:
- For patients who are either unable to receive BCG therapy, or BCG unresponsive, what other therapeutic options are currently available?
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Urology Times
1
Trial to evaluate ivonescimab plus enfortumab vedotin in urothelial carcinoma
2
Neil Baum, MD, and Abraham Morgentaler, MD, discuss the history of testosterone and prostate cancer
3
FDA clears Revi Extend implant for urgency urinary incontinence
4
CAPItello-281 Trial Design and Efficacy Data in mHSPC
5













